Consistent with this possibility is our data demonstrating the first evidence that cancer-associated MTOR mutations promote a proliferative advantage over wild type MTOR. The TCGA data set are from primary RCC tumor samples. This evidence concerns the gene MTOR and renal cell carcinoma.